Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 14, Issue 11, Pages 990-999
Publisher
Wiley
Online
2012-05-31
DOI
10.1111/j.1463-1326.2012.01630.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
- (2011) K. Strojek et al. DIABETES OBESITY & METABOLISM
- Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes
- (2011) Ann V. Schwartz JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Diabetes and fractures: an overshadowed association
- (2011) Natasha B Khazai et al. Current Opinion in Endocrinology Diabetes and Obesity
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Differential Effects of PPAR-γ ActivationversusChemical or Genetic Reduction of DPP-4 Activity on Bone Quality in Mice
- (2010) Kimberly A. Kyle et al. ENDOCRINOLOGY
- The Assessment of Fracture Risk
- (2010) Aasis Unnanuntana et al. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
- (2009) J. P.H. Wilding et al. DIABETES CARE
- Pentosidine and Increased Fracture Risk in Older Adults with Type 2 Diabetes
- (2009) Ann V. Schwartz et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates
- (2008) Min Zhang et al. BIOMETRICS
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
- (2008) Y. K. Loke et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2008) Wei Meng et al. JOURNAL OF MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started